Findings

What do systematic reviews say?

5 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 0 · 0%Moderate 4 · 66.7%High 0 · 0%

Fondaparinux plus vitamin K antagonist vs usual care

Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis

Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.8 [0.43, 1.47]
2 studies · 2658 participants
Moderate

Fondaparinux plus vitamin K antagonist vs usual care

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).

2 findings from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.15 [0.39, 3.44]
2 studies · 2645 participants
Moderate
Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.05 [0.64, 1.71]
2 studies · 2645 participants
Moderate

Fondaparinux plus vitamin K antagonist vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.93 [0.45, 1.91]
2 studies · 2645 participants
Moderate

Fondaparinux plus vitamin K antagonist vs usual care

Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fondaparinux plus vitamin K antagonist vs usual care

All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis

It is very uncertain whether fondaparinux plus vitamin K antagonist changes all harmful effects compared with standard therapy (very low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.84 [0.76, 0.93]
1 study · 2192 participants
Very low